Breaking News, Collaborations & Alliances

Bayer, OncoMed Enter Anti-Cancer Stem Cell Pact

Bayer Schering Pharma and OncoMed Pharmaceuticals entered into a global strategic alliance to discover, develop and commercialize anti-cancer stem cell therapeutics targeting the Wnt signaling pathway.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Bayer Schering Pharma and OncoMed Pharmaceuticals entered into a global strategic alliance to discover, develop and commercialize anti-cancer stem cell therapeutics targeting the Wnt signaling pathway. Cancer stem cells are believed to play a significant role in the metastasis and recurrence of cancer and agents targeting the Wnt pathway have the potential to be developed as pan-tumor drugs. The two companies will share technology and experience to discover and develop small molecule inhibit...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters